PARP
Navigation Links
PARP in Medical News
...ed to enroll more than 100 participants in this 420-patient study. Enrollment in the study opened July 16 in centers nationwide.
"The BSI-201 parp Inhibitor is a potential game changing therapy in the treatment of triple-negative breast cancer. US Oncology Research is excited about the opportunit...
...uch as leukemia. Phase II trials for several tumor types began this year. parp Inhibitors (ABT-888) DNA damaging agents remain some of the most successf...caused by these agents used to treat cancer and render them ineffective. As parp activity is often increased in cancer cells, it provides these cells with a...
New Cancer Drug Fights Tumors in Those With BRCA Mutations
... protein involved in DNA repair. Healthy cells use parp to repair themselves, but cancer cells do the same...eam concluded. Iglehart thinks that combining a parp inhibitor with chemotherapy drugs that damage DNA ...over the cliff that would be only susceptible to a parp inhibitor," he said. In addition, "PARP inhibit...BRIT1 allows DNA repair teams access to damaged sites
...ent Having shown that BRIT1 deficiency impairs HR repair, Peng said one solution the team is examining is to treat cancer cells lacking BRIT1 with parp inhibitors, drugs that specifically kill HR-deficient cancer cells. BRIT1 mutations are known to cause a neurological condition called primary micr...New Insights, Inroads Against Breast, Ovarian Cancers
...esults with an entirely new class of drugs, called parp inhibitors -- the first targeted therapy for so-ca...eive chemo alone, the other half to chemo plus the parp inhibitor BSI-201. Those receiving the combina...pared with standard chemo. The second phase II parp inhibitor trial involved 54 women with advance bre...Sanofi-aventis Announces Good First-quarter 2009 Performance
...ncology R&D portfolio with the addition of the parp inhibitor BSI-201 and demonstrating our strong com...lopment: -- BSI-201, a parp inhibitor, has entered our portfolio following ...could be a potential first-in-class parp inhibitor, and is currently in phas......uch as leukemia. Phase II trials for several tumor types began this year. parp Inhibitors (ABT-888) DNA damaging agents remain some of the most successf...caused by these agents used to treat cancer and render them ineffective. As parp activity is often increased in cancer cells, it provides these cells with a...
Study reveals why certain ovarian cancers develop resistance to platinum-based chemotherapy
...ave a secondary mutation on their BRCA2 gene, their cancer likely would be resistant not only to platinum-based compounds but also other drugs such as parp inhibitors. Testing whether relapsed tumors have a secondary mutation of BRCA2 may be important to predict clinical outcome, Taniguchi said. The rese...Americans Optimistic About the War on Cancer
...cientists from independent academic institutions and Abbott will present data on several of Abbott's investigational anti-cancer compounds including a parp inhibitor (ABT-888) that seeks to enhance the effectiveness of common cancer therapies, a multi-targeted kinase inhibitor (ABT-869) being investigated...Astrazeneca's Investigational Cancer Therapies Revealed at ASCO
...s been studied in a range of tumor types in Phase I studies. The study presented today at ASCO showed that treatment with AZD2281 led to inhibition of parp functional activity in both surrogate and tumor tissue, and reported that strong signals were detected in hereditary ovarian cancer. Between 5% and 10...PARP in Medical Technology
- Strategic Collaboration with the Gynecologic Oncology Group -
BRISBANE, Calif., May 28 /PRNewswire/ -- BiPar Sciences, Inc. today
announced it has expanded its clinical trials program through the
initiation of an additional Phase 2 study of its lead product candidate
BSI-201. The trial w...
- First in human clinical data highlight safety profile of BSI-201 in subjects with advanced solid tumors - BRISBANE, Calif., May 15 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that data su...
BRUSSELS, Belgium and BRISBANE, Calif., Nov. 15 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced it has initiated a Phase 2 study of its lead PARP inhibitor, BSI-201, in patients with triple-negative breast canc...
SAN FRANCISCO, Oct. 24 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced data demonstrating that BSI-401 inhibited pancreatic cancer cell growth in vitro and in vivo, both alone and in combination with oxaliplati...
BRISBANE, Calif., Sept. 25 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that it has hired industry veterans Eric D. Malek as vice president of corporate development and Deborah A. Thomas as vice president fo...
BEVERLY, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Inotek Pharmaceuticals Corporation announced today the presentation of positive Phase 2 clinical data demonstrating the safety of INO-1001 as well as the potential for INO-1001 as a preventative agent for cardiac reperfusion injury. The study was cond...
BEVERLY, Mass.--(BUSINESS WIRE)--Apr 10, 2007 - Inotek Pharmaceuticals Corporation announced today the publication in the journal Stroke of preclinical animal data showing that the administration of a poly(ADP-Ribose) polymerase (PARP) inhibitor has a large protective effect on the survival of cert...
...ed to enroll more than 100 participants in this 420-patient study. Enrollment in the study opened July 17 in centers nationwide. "The BSI-201 parp Inhibitor is a potential game changing therapy in the treatment of triple-negative breast cancer. US Oncology Research is excited about the opportunit...
...o schedules and other ASCO information and resources, visit http://www.asco.org/presscenter . About BSI-201 Among other investigational parp inhibitors in the industry, BSI-201 is the furthest along in clinical development in metastatic TNBC. BSI-201 is currently being evaluated for its pot...
- First in human clinical data highlight safety profile of BSI-201 in subjects with advanced solid tumors - BRISBANE, Calif., May 15 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that data su...
BRUSSELS, Belgium and BRISBANE, Calif., Nov. 15 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced it has initiated a Phase 2 study of its lead PARP inhibitor, BSI-201, in patients with triple-negative breast canc...
SAN FRANCISCO, Oct. 24 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced data demonstrating that BSI-401 inhibited pancreatic cancer cell growth in vitro and in vivo, both alone and in combination with oxaliplati...
BRISBANE, Calif., Sept. 25 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that it has hired industry veterans Eric D. Malek as vice president of corporate development and Deborah A. Thomas as vice president fo...
BEVERLY, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Inotek Pharmaceuticals Corporation announced today the presentation of positive Phase 2 clinical data demonstrating the safety of INO-1001 as well as the potential for INO-1001 as a preventative agent for cardiac reperfusion injury. The study was cond...
BEVERLY, Mass.--(BUSINESS WIRE)--Apr 10, 2007 - Inotek Pharmaceuticals Corporation announced today the publication in the journal Stroke of preclinical animal data showing that the administration of a poly(ADP-Ribose) polymerase (PARP) inhibitor has a large protective effect on the survival of cert...
...ed to enroll more than 100 participants in this 420-patient study. Enrollment in the study opened July 17 in centers nationwide. "The BSI-201 parp Inhibitor is a potential game changing therapy in the treatment of triple-negative breast cancer. US Oncology Research is excited about the opportunit...
...o schedules and other ASCO information and resources, visit http://www.asco.org/presscenter . About BSI-201 Among other investigational parp inhibitors in the industry, BSI-201 is the furthest along in clinical development in metastatic TNBC. BSI-201 is currently being evaluated for its pot...
BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
... action in oncology. Our existing platform is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. BSI-201 is the lead parp inhibitor program in Phase 2 clinical trials in multiple solid tumor settings. ...PARP in Biological News
Mechanism identified for promising neurological drug
...inocycline turns out to be an extraordinarily good parp inhibitor, better than most of the drugs that are marketed as parp inhibitors," he says. The paper appears in the...to this time, we've been doing that with bona fide parp inhibitors. We intend now to look at minocycline i...PARP in Biological Technology
A Further Step in Understanding Apoptosis Direct Detection of PARP Cleavage
Detection of early apoptotic events has become quite relevant since many studies have demonstrated that abnormalities in cell death regulation cause a variety of diseases and pathological conditions accompanied either b...A DELFIA Assay for Inhibition of PARP
The DELFIA time-resolved fluorescence assay for inhibition of poly(ADP-ribose) polymerase (PARP) is a 96-well microplate assay that measures the inhibition of PARP-activated incorporation of biotinylated nicotinamide adenine diphsophate (NAD). The incorporation is detected using Europiuml...Sanofi-aventis Announces Second Quarter 2009 Results
... the biotechnology company Exelixis SAR 407899, a rho-kinase inhibitor, entered Phase II in erectile dysfunction. BSI-201, a parp inhibitor, developed by BiPar Sciences (recently acquired by sanofi-aventis) entered Phase III in July. This pivotal study will evaluate the product i...BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
...o DNA repair that is upregulated in certain tumors. The company's lead compound, BSI-201, has entered a series of Phase 2 trials in tumors types where parp is overexpressed. The first of those trials will evaluate BSI-201 in patients with "triple negative" breast cancer, and BiPar expects to begin trials ......e Protein MIA as a Marker for Chondrocytes in Research Samples A Further Step in Understanding Apoptosis Direct Detection of parp Cleavage Detection of mRNAs on Cryosections of the Cardiovascular System Using DIG-Labeled RNA Probes ...
PARP in Biological Products
PARP Inhibitor XI, DR2313 from Calbiochem
Description:...M LIGHT. PACKAGED UNDER INERT GAS. A brain-permeable and water soluble pyrimidinone compound that acts as a potent and NAD + -competitive inhibitor of parp (IC 50 = 200 nM and 240 nM for rhPARP1 and rmPARP2, respectively) with little activity against the dehydrogenase activity of GAPDH, ADH, LDH, or the ...Company:Calbiochem
PARP Cleavage Detection Kit from Calbiochem
Description:...e) polymerase (PARP) cleavage by Western blotting. parp is an enzyme implicated in DNA damage and repair mechanisms. During apoptosis, parp is cleaved by caspase-3. Cleavage of parp from the native 116 kDa to 85 kDa is a hallmark of...Company:Calbiochem
Other TagsTomTomTomTomTomTomTomTomTomsettlesettleOther Contentsgravidarumhyperemesishyperkalemia
KoulopoulosTomarrivalhasnlawsuitscruxindustriesspeedometershandcuffpavilionPlattevilleliasonsettleVisiplex
(Date:11/29/2009)...get blamed for something leads to more self-defens...DAY, Nov. 29 (HealthDay News) -- The blame game is...the target is innocent. , Researchers found tha... problem, even if it,s an unfair accusation, they,...oo. , "When we see others protecting their ego...
(Date:11/28/2009)...GO, Nov. 28 Welcome to syngo&#...r the clinical routine from Siemens Healthcare. ...ons System (PACS) from Siemens where 2D, 3D, and... .plaza is poised to change the way multimodality ...nnovation at the 95th Scientific Assembly and An...
(Date:11/27/2009)...D, Mass., Nov. 27 GSI Gr...pplier of precision technology products and semico...eting of the Company,s shareholders has been sched...ation of the meeting will be announced in due cour... a requisition notice from Stephen Bershad, a hold...
(Date:11/27/2009)...ER, N.Y., Nov. 27 Preve...vider and fortunately every year, new vaccines are...do all vaccines boost immunity for the same period...r shots, needed to keep immunity strong? ,, I... the American Academy of Pediatrics, Michael Pichi...
(Date:11/27/2009)...ing unprecedented medical, economic burdens, study... News) -- The number of people with diabetes in th...t 25 years, a new study predicts. , That would ...le with the disease, up from 23.7 million today. ,... with diabetes will triple, the study also warns, ...
Breaking Medicine News(10 mins):Health News:When Accusations Start to Fly, They Multiply 2Health News:Siemens Healthcare Unveils syngo.plaza at RSNA 2009 2Health News:Siemens Healthcare Unveils syngo.plaza at RSNA 2009 3Health News:GSI Group Calls Shareholders Meeting 2Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3(Date:11/25/2009)...s vital to your health as what you eat, found rese...es. Their experiments in mice revealed that the da... liverthe body,s metabolic clearinghouseis mostly ...rcadian clock as conventional wisdom had it. , ...e number of genes completely independent of the ci...
(Date:11/24/2009)... named 12 new grant recipients for 2009. The award...k across a broad spectrum of lupus research. All w...tential to drive scientific discovery to ultimatel...systemic lupus. , The 2009 grants go to both new...on and include interdisciplinary and highly promis...
(Date:11/24/2009)...hat may help gut bacteria bind to the gastrointest... producers to identify strains that are likely to ...to interact with cells lining the gut to have a be... the gut they are more likely to stick around long... Juge from the Institute of Food Research. IFR is...
Breaking Biology News(10 mins):Feeding the clock 2Feeding the clock 3Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3A sticky solution for identifying effective probiotics 2Analysis confirms that nano related research has strong multidisciplinary roots 13875 1Analysis confirms that nano related research has strong multidisciplinary roots 13875 2Analysis confirms that nano related research has strong multidisciplinary roots 13875 3Analysis confirms that nano related research has strong multidisciplinary roots 13875 4Mounting a multi layered attack on fungal infections 9820 1Mounting a multi layered attack on fungal infections 9820 2Jerry Lewis MDA Telethon Achieves 2460 5 Million 56344 1Jerry Lewis MDA Telethon Achieves 2460 5 Million 56344 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |